Circulating parathyroid hormone-related protein (109-141) in malignancy-associated hypercalcemia. 1996

K Nagasaki, and K Otsubo, and N Kajimura, and R Tanaka, and H Watanabe, and Y Tachimori, and H Kato, and H Yamaguchi, and D Saito, and T Watanabe, and I Adachi, and K Yamaguchi
Growth Factor Division, National Cancer Center Research Institute, Tokyo.

For differential diagnosis between hypercalcemia-induced bone metastasis and humoral hypercalcemia of malignancy (HHM), serum parathyroid hormone-related protein (PTHrP) concentrations were measured in normal subjects and patients with malignancy-associated hypercalcemia according to the presence or absence of bone metastasis, using a new sensitive PTHrP(109-141) radioimmunoassay system. The serum PTHrP(109-141) levels in all of 14 patients without bone metastasis were significantly higher than those in normal subjects. However, in four patients with hypercalcemia associated with bone metastasis the levels were nearly the same as those in normal subjects. The time course in two hypercalcemic patients with esophageal carcinoma revealed that serum PTHrP(109-141) levels were elevated before hypercalcemia developed and that changes in PTHrP(109-141) and corrected serum calcium levels were significantly correlated. These findings suggest that determination of serum PTHrP(109-141) may be clinically important not only for differential diagnosis of HHM but also as a useful predictive marker of hypercalcemia.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus

Related Publications

K Nagasaki, and K Otsubo, and N Kajimura, and R Tanaka, and H Watanabe, and Y Tachimori, and H Kato, and H Yamaguchi, and D Saito, and T Watanabe, and I Adachi, and K Yamaguchi
May 1998, Leukemia & lymphoma,
K Nagasaki, and K Otsubo, and N Kajimura, and R Tanaka, and H Watanabe, and Y Tachimori, and H Kato, and H Yamaguchi, and D Saito, and T Watanabe, and I Adachi, and K Yamaguchi
January 2000, Clinica chimica acta; international journal of clinical chemistry,
K Nagasaki, and K Otsubo, and N Kajimura, and R Tanaka, and H Watanabe, and Y Tachimori, and H Kato, and H Yamaguchi, and D Saito, and T Watanabe, and I Adachi, and K Yamaguchi
January 1990, Advances in clinical chemistry,
K Nagasaki, and K Otsubo, and N Kajimura, and R Tanaka, and H Watanabe, and Y Tachimori, and H Kato, and H Yamaguchi, and D Saito, and T Watanabe, and I Adachi, and K Yamaguchi
April 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
K Nagasaki, and K Otsubo, and N Kajimura, and R Tanaka, and H Watanabe, and Y Tachimori, and H Kato, and H Yamaguchi, and D Saito, and T Watanabe, and I Adachi, and K Yamaguchi
January 1994, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
K Nagasaki, and K Otsubo, and N Kajimura, and R Tanaka, and H Watanabe, and Y Tachimori, and H Kato, and H Yamaguchi, and D Saito, and T Watanabe, and I Adachi, and K Yamaguchi
January 1989, Toxicologic pathology,
K Nagasaki, and K Otsubo, and N Kajimura, and R Tanaka, and H Watanabe, and Y Tachimori, and H Kato, and H Yamaguchi, and D Saito, and T Watanabe, and I Adachi, and K Yamaguchi
September 1989, Endocrinology and metabolism clinics of North America,
K Nagasaki, and K Otsubo, and N Kajimura, and R Tanaka, and H Watanabe, and Y Tachimori, and H Kato, and H Yamaguchi, and D Saito, and T Watanabe, and I Adachi, and K Yamaguchi
January 1994, Annual review of medicine,
K Nagasaki, and K Otsubo, and N Kajimura, and R Tanaka, and H Watanabe, and Y Tachimori, and H Kato, and H Yamaguchi, and D Saito, and T Watanabe, and I Adachi, and K Yamaguchi
January 1997, Cancer treatment and research,
K Nagasaki, and K Otsubo, and N Kajimura, and R Tanaka, and H Watanabe, and Y Tachimori, and H Kato, and H Yamaguchi, and D Saito, and T Watanabe, and I Adachi, and K Yamaguchi
November 1994, Annals of nuclear medicine,
Copied contents to your clipboard!